Clal Biotech (CBI) Financial Statements
Clal Biotech Financial Overview
Clal Biotech's market cap is currently $35.92M. The company's EPS TTM is $-0.06; its P/E ratio is -3.95; and it has a dividend yield of 11.43%. Clal Biotech has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 835.00K | $ 433.00K | $ 104.00K | $ 370.00K | $ 224.00K |
| Gross Profit | $ 364.00K | $ -183.00K | $ 104.00K | $ 370.00K | $ 224.00K |
| Operating Income | $ -18.41M | $ -6.34M | $ -10.18M | $ -27.42M | $ -77.59M |
| EBITDA | $ -19.83M | $ -6.34M | $ -24.02M | $ 64.22M | $ -55.08M |
| Net Income | $ -13.32M | $ -62.46M | $ -31.05M | $ -61.74M | $ -89.58M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 1.69M | $ 5.01M | $ 13.36M | $ 12.88M | $ 53.05M |
| Total Assets | $ 41.83M | $ 67.69M | $ 158.39M | $ 182.69M | $ 444.92M |
| Total Debt | $ 17.75M | $ 20.84M | $ 35.76M | $ 36.73M | $ 11.68M |
| Net Debt | $ 16.07M | $ 16.89M | $ 30.03M | $ 29.29M | $ -41.37M |
| Total Liabilities | $ 18.95M | $ 21.52M | $ 36.98M | $ 37.79M | $ 106.55M |
| Stockholders' Equity | $ 20.20M | $ 36.63M | $ 99.36M | $ 126.03M | $ 172.59M |
| Cash Flow | |||||
| Free Cash Flow | $ -4.07M | $ -6.48M | $ -8.52M | $ -60.31M | $ -42.92M |
| Operating Cash Flow | $ -4.07M | $ -6.48M | $ -8.51M | $ -59.04M | $ -41.33M |
| Investing Cash Flow | $ 2.70M | $ 20.00M | $ 7.66M | $ -10.96M | $ 79.18M |
| Financing Cash Flow | $ -929.00K | $ -15.55M | $ -1.18M | $ 20.05M | $ -51.54M |
Currency in ILS